Характеристика лекарственно-индуцированных кожных реакций в многопрофильном скоропомощном стационаре

This prospective study was carried out in a period of 1 year on the basis of the multifield emergency hospital in the departments of therapy, urology and purulent surgery. On the basis of data of the screening method and the method of spontaneous messages a group of 347 patients with skin reactions, which potentially associated with the intake of medicines was highlighted in. Among them, there were 179 patients with non drug associated skin reactions and 168 patients with drug-induced skin reactions. The most common cutaneous drug reactions (CDR) were: acute urticaria, angioedema; drug toxidermia; allergic dermatitis; hemorrhagic vasculitis. Mostly СDR were caused by the following groups of drugs: b-lactam antibiotics; fluoroquinolones; drugs, improving cerebral blood flow; rentgencontrasting substances.Настоящее проспективное исследование осуществлялось в течение 1 года на базе многопрофильного скоропомощного стационара в отделениях терапии, урологии и гнойной хирургии. На основании данных скринингового метода и метода спонтанных сообщений была выделена группа пациентов количеством 347 человек с кожными реакциями, потенциально связанными с приемом лекарственных средств. Среди них было 179 пациентов c кожными реакциями, не связанными с приемом лекарственных средств (ЛС) и 168 пациентов с лекарственно-индуцированными кожными реакциями. Наиболее распространенными кожными лекарственными реакциями (КЛР) были: острая крапивница, отек Квинке; лекарственные токсидермии; аллергические дерматиты; геморрагические васкулиты. Чаще всего КЛР вызывали следующие группы ЛС: b-лактамные антибиотики; фторхинолоны; ЛС, улучшающие мозговой кровоток; рентгеноконтрастные вещества

Venous thromboembolism in patients with heart failure

This review is focussed on the problem of venous thromboembolism in patients with heart failure (HF). The results of the major clinical trials of antithrombotic therapy in HF patients are presented. The authors discuss comparative effectiveness, safety, and tolerability of unfractionated heparins, low molecular weight heparins, and fondaparinux. The results of the two trials, MAGELLAN and ADOPT, are expected to clarify the clinical potential of such oral anticoagulants as rivaroxaban and apixaban (Factor Xa inhibitors). The problem of low rates e of preventive antithrombotic administration is emphasized

Effects of fluvastatin, valsartan, and their combination on endothelial function in patients with arterial hypertension and dyslipidemia

Aim. To study the effects of an angiotensin II receptor antagonist (ARA II) valsartan, a statin (fluvastatin XL), and their combination on endothelial function (EF) in patients with arterial hypertension (AH) and dyslipidemia (DLP). Material and methods. In total, 30 patients with untreated, non-complicated Stage I-II AH and DLP IIA or IIB were randomised for 8-week monotherapy with valsartan or fluvastatin XL, with the subsequent addition of the second component, fluvastatin XL or valsartan, respectively. Results. Valsartan monotherapy was associated with a reduced increase in linear blood flow velocity (LFV) during the reactive hyperemia test (RHT) - 177,7 +/- 5,8 vs. 170,0 +/- 4,9% (p0,05). Eight-week monotherapy with fluvastatin XL (80 mg/d) was linked to moderate but statistically significant reduction (-2%) in systolic blood pressure (SBP), with no effect on diastolic BP level. In RHT, LFV increase did not change, but EF improved, as manifested in BA EDVD increase. Prolonged combined therapy resulted in further EF improvement. Conclusion. Combined fluvastatin XL and valsartan therapy in patients with untreated Stage I-II AH and DLP IIA or IIB improved EF more effectively than valsartan or fluvastatin XL monotherapy

Venous thromboembolism in patients with heart failure

This review is focussed on the problem of venous thromboembolism in patients with heart failure (HF). The results of the major clinical trials of antithrombotic therapy in HF patients are presented. The authors discuss comparative effectiveness, safety, and tolerability of unfractionated heparins, low molecular weight heparins, and fondaparinux. The results of the two trials, MAGELLAN and ADOPT, are expected to clarify the clinical potential of such oral anticoagulants as rivaroxaban and apixaban (Factor Xa inhibitors). The problem of low rates e of preventive antithrombotic administration is emphasized